PURE Biosciences

PURE · OTC

$0.072+$0.0059 (+8.93%)TodayMarket closed ·
Prev close $0.0661

Key indicators

PURE profitability and balance sheet ratios

EPS -$0.0056 in Apr 2026, against -$0.0052 a year earlier.

EPS by quarter
PeriodEPS
Jul 2024-$0.0068
Oct 2024-$0.0062
Jan 2025-$0.0071
Apr 2025-$0.0052
Jul 2025-$0.003
Oct 2025-$0.0041
Jan 2026-$0.007
Apr 2026-$0.0056

Where the money went

Q3 FY13, from revenue to net income

PURE Biosciences brought in $0.3M of revenue in Q3 FY13, +24.6% on a year earlier. It made a net loss of $1.5M.

Revenue
$0.3M
Costs, expenses and taxes
$1.8M
Net income
−$1.5M
Net margin
-594.6%

Income statement

Revenue and profit by reporting period

Revenue
Net income
PURE income statement, quarterly
Line itemQ1 FY13Q2 FY13Q3 FY13
Revenue$0.1M$0.3M$0.3M
Gross profit$0.1M$0.2M$0.2M
Operating income−$1.8M−$1.8M−$1.6M
Net income−$2.2M−$1.8M−$1.5M
Diluted EPS-$0.25-$0.17-$0.14

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
PURE balance sheet, quarterly
Line itemOct 2025Jan 2026Apr 2026
Total assets$1.2M$0.8M$1.6M
Total liabilities$6.7M$7.1M$7.4M
Shareholder equity−$5.5M−$6.3M−$5.8M
Cash and short-term investments$0.4M$0.2M$1.0M
Total debt$5.7M$6.1M$6.5M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
PURE cash flow, quarterly
Line itemQ1 FY13Q2 FY13Q3 FY13
Operating cash flow−$1.2M−$1.5M−$0.8M
Investing cash flow−$0.1M−$0.1M−$0.1M
Financing cash flow$2.9M$0.0M$0.4M
Capital expenditure−$0.0M−$0.0M−$0.0M
Free cash flow−$1.2M−$1.5M−$0.8M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.